Search Within

Genitourinary Oncology Service

Formats
  1. Journal Article (2795)
  2. Meeting Abstract (2525)
  3. Review (121)
  4. Book Section (83)
  5. Editorial (57)
  6. Correspondence (34)
  7. Conference Paper (29)
  8. Guidelines (25)
  9. Research Letter (18)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Solid Tumor Oncology Division (5695)
  2. Department of Medicine (5685)
  3. GSK Faculty (1658)
  4. Human Oncology and Pathogenesis Program (1157)
  5. Department of Pathology and Laboratory Medicine (1129)
  6. Surgery (1021)

More Groups

People
  1. Robert Motzer (1252)
  2. Howard Scher (1133)
  3. David Solit (785)
  4. Dean Bajorin (664)
  5. Michael Morris (588)
  6. Jonathan Rosenberg (525)

More People

Years
  1. 2025 (203)
  2. 2024 (294)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1713)
  2. Annals of Oncology (304)
  3. Clinical Cancer Research (283)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (123)

More Publications

Publishers
  1. American Society of Clinical Oncology (1780)
  2. American Association for Cancer Research (689)
  3. Oxford University Press (414)
  4. Elsevier Science, Inc. (396)
  5. Elsevier Inc. (380)
  6. Nature Publishing Group (304)

More Publishers

Results (5695)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Axitinib second-line therapy for metastatic renal cell carcinoma (mRCC): Five-year (yr) overall survival (OS) data from a phase II trial
    Meeting Abstract

    Motzer, R. J.; de la Motte Rouge, T.; Harzstark, A. L.; Michaelson, M. D.; Liu, G.; Gruenwald, V.; Ingrosso, A.; Tortorici, M. A.; Bycott, P. W.; Kim, S.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Long-term response to sunitinib for metastatic renal cell carcinoma (mRCC) patients treated on clinical trials at Memorial Sloan-Kettering Cancer Center
    Meeting Abstract

    Molina, A. M.; Jia, X.; Ginsberg, M. S.; Velasco, S.; Feldman, D. R.; Patil, S.; Motzer, R. J.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Effect of abiraterone acetate (AA) on pain control and skeletal-related events (SRE) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) post docetaxel (D): Results from the COU-AA-301 phase III study
    Meeting Abstract

    Logothetis, C.; De Bono, J. S.; Molina, A.; Basch, E. M.; Fizazi, K.; North, S. A.; Chi, K. N.; Jones, R. J.; Goodman, O. B.; Mainwaring, P. N.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • The biology of early-onset colorectal cancer: An examination of tumor markers, pathology, and survival in a large cohort of patients
    Meeting Abstract

    Khan, S. A.; Morris, M.; Idrees, K.; Gimbel, M.; Rosenberg, S.; Zeng, Z.; Shia, J.; La Quaglia, M. P.; Paty, P.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Initial study of bone scan tumor area for early surrogate outcome assessment in patients with metastatic castration-resistant prostate cancer
    Meeting Abstract

    Kim, H. J.; Brown, M. S.; Chu, G. H.; Gjertson, D. W.; Auerbach, M.; Poon, C.; Vidovic, A.; Ramakrishna, B.; Morris, M. J.; Larson, S. M.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • A pooled analysis of the efficacy and safety of sunitinib in elderly patients (pts) with metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Hutson, T. E.; Bukowski, R. M.; Rini, B. I.; Gore, M. E.; Larkin, J. M. G.; Figlin, R. A.; Barrios, C. H.; Escudier, B.; Lin, X.; Fly, K. D.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Association of germ-line variation with platinum-based chemotherapy response in patients (pts) with urothelial carcinoma (UC)
    Meeting Abstract

    Gallagher, D. J.; Joseph, V.; Hamilton, R. J.; Ostrovnaya, I.; Garcia-Grossman, I. R.; Riches, J. C.; Regazzi, A. M.; Przybylo, J. A.; Gaudet, M.; Milowsky, M. I.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Risk of rash and stomatitis with temsirolimus, a mammalian target of rapamycin (mTOR) inhibitor: A meta-analysis
    Meeting Abstract

    Gomez Fernandez, C.; Balagula, Y.; Wu, S.; Su, X.; Feldman, D. R.; Rathkopf, D. E.; Lacouture, M. E.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • A phase II multicenter evaluation of ARQ 197 monotherapy in patients with relapsed or refractory germ cell tumors (GCTs)
    Meeting Abstract

    Feldman, D. R.; Einhorn, L. H.; Quinn, D. I.; Horwich, A.; Loriot, Y.; Joffe, J. K.; Vaughn, D. J.; Flechon, A.; Hajdenberg, J.; Pande, A. U.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • A randomized phase II study of cetuximab (C) every 2 weeks at either 500 or 750 mg/m(2) for patients (Pts) with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)
    Meeting Abstract

    Fury, M. G.; Sherman, E. J.; Lisa, D. M.; Agarwal, N.; Algazy, K. M.; Brockstein, B.; Langer, C. J.; Lim, D.; Mehra, R.; Rajan, S. K.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save